Please login to the form below

Not currently logged in
Email:
Password:

Ex J&J VP joins board of Immune

Cameron Durrant also has senior experience at Pharmacia
cameron durrant immune

Immune Pharmaceuticals has added veteran pharma experience to its board with the appointment of Cameron Durrant.

Immune will benefit from Durrant's knowledged of the iundstry gained during time in roles such as worldwide VP at Johnson & Johnson and VP, Pharmacia until its acquisition by Pfizer.

His other experience includes serving as CEO of PediatRx and CEO of PediaMed Pharmaceuticals as part of a career in pharma that began at Merck & Co.

Dr Daniel Teper, Immune's chairman and CEO, commented: "I have been privileged to work with Cameron in several of his leadership roles at GSK, Pharmacia, J&J and PediaMed.

“His entrepreneurial drive along with the discipline acquired at leading companies and his extensive board experience at public and private companies will be a strong asset as Immune expands its clinical development and commercialisation activities."

Immune specialises in developing antibodies to treat patients with inflammatory diseases and cancer. Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.

21st July 2014

From: Sales

Share

Tags

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company
Health Unlimited

Health Unlimited is a global health consultancy and communications agency built by specialists with unmatched experience, perspective and expertise. For...

Latest intelligence

Are patient recruitment and retention rates rising or falling?
First up, the good news. Over the past seven years, clinical trial recruitment rates have been on the rise....
Could formulary intelligence be your brand differentiator?
Proprietary research, and the COVID-19 experience, shows how formulary intelligence can drive competitive advantage at launch...
Lara Meyer
How COVID-19 is accelerating the threat of antimicrobial resistance
Why antimicrobial resistance needs to be addressed with the same urgency as COVID-19...

Infographics